Hippocampal lipids linked to brain disorders
The hippocampus is a fundamental brain region for memory processes, and its function is impaired early in the onset of neurodegenerative disorders such as Alzheimer’s disease, or AD.
Most studies addressing the hippocampus have considered it as a whole structure, but it also can be divided into subregions along its longitudinal axis, segregating dorsal and ventral poles. For instance, the dorsal hippocampus, or DH, contributes differentially to specific dimensions of spatial memory, while the ventral hippocampus, or VH, is proposed to be implicated predominantly in behaviors linked to emotions.
Lipids are major brain constituents, so we performed mass spectrometry lipidomic analysis of hippocampal subregions along the longitudinal axis. Within the lipidomic signatures we uncovered, we observed that the DH presents increased levels of phosphatidic acid and decreased levels of phosphatidylcholine compared to the VH, potentially implicating the phospholipase D, or PLD, pathway in DH–VH axis regulation.
Although six PLDs are found in mammals, only PLD1 and PLD2 have reported canonical PLD activity, which is based on the hydrolysis of phosphatidylcholine in the presence of water to free choline and phosphatidic acid, a known second messenger signaling lipid. Using mice that were genetically altered to lack Pld1 and Pld2 genes, we gathered data to support the hypothesis that PLD1 and PLD2 are the only contributors to PLD activity in the mouse forebrain.
PLD1 ablation significantly decreased the hippocampal levels of phosphatidic acid, affecting predominantly the DH lipidome, but upon PLD2 ablation, only minor lipid changes occurred, including increased PLD products suggesting PLD1 upregulation.
Since PLD1 was the main PLD activity source, we then focused predominantly on characterizing the effects of PLD1 ablation and showed that the mice lacking Pld1 presented specific deficits in novel object recognition and social interaction, disruption in dendritic arborization, and altered synaptic plasticity in the DH. Overall, we determined that PLD1 ablation impairs hippocampal functioning, predominantly affecting the DH, which, due to its allocated functions, is predicted to be particularly affected in Alzheimer’s disease.
We previously had observed that PLD2 ablation is protective in mice genetically altered to have Alzheimer’s. Future studies should address cross-regulation mechanisms between PLD1 and PLD2 and how these can be used to develop therapeutic strategies to treat or prevent hippocampal dysfunction and memory deficits.
Want more lipid research news?
Check out Lipid Trends, a curated collection of hot picks from the world of lipid research, brought to you by LIPID MAPS.
Enjoy reading ASBMB Today?
Become a member to receive the print edition monthly and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
The quest to treat and cure xerostomia
Blake Warner, chief of the Salivary Disorders Unit at the NIH talks about his lab’s efforts to develop treatments for dry mouth.
There's more to blue cheese than just the stench
Virginia Tech researchers discovered a way to synthesize a compound in the mold of blue cheese that has antibacterial and anticancer properties.
Engineering cells to broadcast their behavior can help scientists study their inner workings
Researchers can use waves to transmit signals from the invisible processes and dynamics underlying how cells make decisions.
From the journals: JBC
Lung cancer cells resist ferroptosis. ORMDL3 in ulcerative colitis. Novel genetic variants in thyroid cancer. Read about these recent papers.
Seeking the sweet spot to beat a pig parasite
Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.
Radioactive drugs strike cancer with precision
The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.